Predictors of severe and critical disease in pregnant women with SARS-CoV-2

Meghana A. Limaye, Ashley S. Roman, Megan E. Trostle, Pooja Venkatesh, Meralis Lantigua Martinez, Sara G. Brubaker, Judith Chervenak, Lili S. Wei, Parita Sahani, Tracy B. Grossman, Jessica A. Meyer and Christina A. Penfield

Department of Obstetrics and Gynecology, New York University Grossman School of Medicine, New York, NY, USA

ABSTRACT

Background/Objective: SARS-CoV-2 continues to spread widely in the US and worldwide. Pregnant women are more likely to develop severe or critical illness than their non-pregnant counterparts. Known risk factors for severe and critical disease outside of pregnancy, such as asthma, diabetes, and obesity have not been well-studied in pregnancy. We aimed to determine which clinical and pregnancy-related factors were associated with severe and critical COVID illness in pregnancy.

Study design: This was a retrospective cohort study of women with confirmed intrauterine pregnancy and positive nasopharyngeal swab for SARS-CoV-2 who presented to an academic medical center in New York City from 1 March 2020 to 1 July 2020. Severe and critical COVID-19 disease was defined by World Health Organization criteria. Women with severe/critical disease were compared to women with asymptomatic/mild disease. Continuous variables were compared with Mann–Whitney or t-test and categorical variables were compared using chi-square and Fisher’s exact. Statistical significance was set at $p < .05$. Multivariable logistic regression was performed including variables that were significantly different between groups.

Results: Two hundred and thirty-three patients were included, 186 (79.8%) with asymptomatic/mild disease and 47 (20.2%) with severe/critical disease. Women with asymptomatic/mild disease were compared to those with severe/critical disease. Women with severe/critical disease were more likely to have a history of current or former smoking (19.6 vs. 5.4%, $p = .004$), COVID-19 diagnosis in the 2nd trimester (42.6 vs. 11.8%, $p = .001$), and asthma or other respiratory condition (21.3 vs. 7.0%, $p = .01$). Women with severe/critical disease were more likely to have cesarean delivery (35.5 vs. 15.6%, $p < .01$) and preterm delivery <37 weeks (25.8 vs. 3.8%, $p < .01$). After adjustment, history of smoking remained significantly predictive of severe/critical disease [aOR 3.84 (95% CI, 1.25–11.82)].

Conclusion: Pregnant women with a history of smoking, asthma, or other respiratory condition, and COVID-19 diagnosis in the second trimester of pregnancy were more likely to develop severe/critical disease. These findings may be useful in counseling women on their individual risk of developing the severe or critical disease in pregnancy and may help determine which women are good candidates for vaccination during pregnancy.

Introduction

In March 2020, widespread community transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, became a global public health crisis. As of 24 April 2021, more than 32 million people in the US and 146 million people globally had been infected [1]. Despite increasing rates of vaccination, widespread transmission is ongoing and hospitalizations and deaths continue to rise. It remains unclear why some develop a severe infection while others remain asymptomatic. Risk factors for severe disease outside pregnancy include obesity, smoking, preexisting conditions, such as asthma, diabetes, and kidney disease, and age >65, and similar risk factors have been implicated in pregnancy as well [2,3]. Additionally, women infected in pregnancy are more likely to develop severe or critical disease than non-pregnant counterparts [4–6]. We aimed to determine which factors were associated with severe and critical COVID disease in pregnancy in a cohort of pregnant women infected with SARS-CoV-2 in New York City, an early epicenter of the pandemic. We hypothesized that medical comorbidities, such as obesity and asthma, as well as trimester of diagnosis and pregnancy-specific comorbidities, such
as preeclampsia and gestational diabetes, would impact the severity of disease in pregnancy.

Methods

We performed an IRB-approved retrospective cohort study of women ages 14–55 with confirmed intrauterine pregnancy and positive nasopharyngeal swab for SARS-CoV-2 who presented to NYU Langone Health-Tisch, NYU Langone Health-Brooklyn, or Bellevue Hospital Center from 1 March 2020 to 1 July 2020. Clinical and demographic characteristics, as well as maternal and neonatal outcomes of included patients, were collected. Charts were reviewed at least 6 weeks after the date of the last positive nasopharyngeal swab in the cohort. Initially, only symptomatic patients were tested for SARS-CoV-2. Universal screening of all patients admitted to labor and delivery was implemented on 14 April 2020 at Bellevue Hospital Center and 4 May 2020 at the two NYU Langone sites. Testing was performed using cobas SARS-CoV-2 assay (Roche), Cepheid Xpert Xpress assay, and BioReference.

Severe COVID-19 infection was defined per World Health Organization criteria as patients with dyspnea, respiratory rate of ≥30 breaths per minute, or blood oxygen concentration <93% on room air [7,8]. Critical disease was defined as respiratory failure requiring intubation, septic shock, and/or multiple organ dysfunction or failure [7,8]. Patients with asymptomatic/mild disease were compared to those with severe/critical disease. Continuous variables were compared with Mann–Whitney or t-test and categorical variables were compared using chi-square and Fisher’s exact.

Statistical significance was set at \( p < .05 \). Multivariable logistic regression was performed including variables that were significantly different between the asymptomatic/mild and severe/critical groups in the univariate analysis. Analysis was performed using SPSS Version 25 (Armonk, NY, USA).

Results

Two hundred and thirty-three patients were included in the analysis. One hundred and forty-two women were tested because of provider suspicion for COVID or symptoms, before the implementation of universal screening on labor and delivery. One hundred and eighty-six (79.8%) had asymptomatic/mild disease and 47 (20.2%) developed severe/critical disease. 36.5% of patients were asymptomatic on presentation, 18.9% reported anosmia or ageusia, 17.6% dyspnea, and 36.1% fever. Two neonates had nasopharyngeal swabs positive for SARS-CoV-2. Eight women (3.4%) required intubation and there were no maternal deaths. Pregnancy outcomes included 191 (82.0%) live births, 4 (1.7%) stillbirths, 7 (3%) first trimester miscarriages or terminations, and 29 (12.4%) ongoing pregnancies at the time of analysis. Two women did not have pregnancy outcomes available. Two stillbirths, at 18 and 36 weeks, occurred in the setting of significant fetal anomalies. Another stillbirth at 27 weeks occurred in pregnancy also complicated by poorly controlled diabetes. All of these patients were asymptomatic for COVID-19 and diagnosed on universal screening. One stillbirth occurred at 36 weeks in a patient with mild COVID-19 in pregnancy with poorly controlled diabetes.

When women with asymptomatic/mild disease were compared to those with severe/critical disease, there were no differences in demographic characteristics, including race/ethnicity and insurance status (Table 1).

Table 1. Demographic characteristics of study population.

| Demographic characteristics | Asymptomatic or mild disease (\( N = 186 \)) | Severe or critical disease (\( N = 47 \)) | \( p \)-Value |
|----------------------------|-----------------------------------------------|-------------------------------------------|----------------|
| Age\(^a\)                   | 30 (9)                                        | 33 (8)                                    | .11†           |
| Race/ethnicity             |                                               |                                           | .15§           |
| Black                      | 17 (9.1)                                      | 6 (12.8)                                  |                |
| Asian                      | 3 (1.6)                                       | 2 (4.3)                                   |                |
| White                      | 85 (45.7)                                     | 15 (31.9)                                 |                |
| Hispanic                   | 59 (31.7)                                     | 21 (44.7)                                 | .42\(\|\)      |
| Other/not recorded         | 22 (11.8)                                     | 3 (6.4)                                   | .26\(\|\)      |
| Interpreter used           | 46 (24.7)                                     | 9 (19.1)                                  |                |
| Insurance status           |                                               |                                           | .75\(\|\)      |
| Medicaid                   | 108 (58.1)                                    | 29 (61.7)                                 | .02†           |
| Private                    | 76 (40.9)                                     | 16 (34.0)                                 |                |
| Uninsured                  | 2 (1.1)                                       | 2 (4.3)                                   |                |
| Parous                     | 131 (70.4)                                    | 32 (68.1)                                 |                |
| BMI at time of diagnosis\(^a\) | 28.9 (6.7)                                   | 29.5 (7.3)                                | .52\(\|\)      |
| BMI > 30 at time of diagnosis | 77 (42.1)                                   | 20 (45.5)                                 | .68\(\|\)      |

All data presented as \( n (\%) \) unless otherwise stated.

\(^a\)Data presented as median (IQR).

\(\|\)Chi-square test used.

\(†\)Mann–Whitney test used.

\(§\)Fisher’s exact test used.
The impact of medical and pregnancy comorbidities on the severity of COVID-19 disease was compared between the two groups (Table 2). Notably, women with severe/critical disease were more likely to have a history of current or former smoking, COVID-19 diagnosis in the 2nd trimester, and asthma or other respiratory condition. Women with obesity and hypertension were no more likely to develop severe/critical disease. There were no differences in blood type, medication use, or hypertensive disease of pregnancy between the groups. Women with severe/critical disease were more likely to have cesarean delivery (35.5 vs. 15.6%, $p < .01$) and preterm delivery <37 weeks (25.8 vs. 3.8%, $p < .01$).

Multivariable logistic regression was performed including trimester at diagnosis, history of smoking, and asthma or other respiratory condition. After adjustment, history of smoking remained significantly predictive of severe/critical disease [aOR 3.84 (95%CI 1.25–11.82), $p < .01$]. The overall model was significant (Hosmer-Lemeshow goodness of fit = 0.85), and correctly predicted 81% of the severe and critical cases.

### Discussion

We found that pregnant women with a history of smoking, asthma, or other respiratory condition, and diagnosis in the second trimester of pregnancy were more likely to develop severe/critical disease. Other medical comorbidities, such as obesity and other pregnancy-associated comorbidities including preeclampsia and gestational diabetes were not associated with the development of severe/critical disease. While asthma and a history of smoking are risk factors for severe/critical disease outside of pregnancy and have been implicated in pregnancy as well [2,3,9], our data suggest a novel finding of increased severity of disease in pregnancy during the second trimester. There may be a biological basis for increased severity in the second trimester, such as changes in lung function and volume or immune system activation as pregnancy progresses, which should be investigated further. We did not find obesity to be a risk factor for severe/critical illness as has been seen in other studies [3,10–12], which may have been related to our small sample size or lower incidence of obesity in New York City. Of note, 33/47 women who developed severe/critical illness did not have a history of asthma or smoking, suggesting that there may be other risk factors for the development of severe/critical illness that has not yet been identified.

This study has several strengths. We included a large cohort of women with SARS-CoV-2 infection in

| Comorbidities                                      | Asymptomatic or mild disease ($N=186$) | Severe or critical disease ($N=47$) | $p$-Value |
|----------------------------------------------------|----------------------------------------|-------------------------------------|-----------|
| Age > 35                                           | 55 (29.6)                              | 16 (34.0)                           | .55       |
| Age > 40                                           | 15 (8.1)                               | 2 (4.3)                             | .54       |
| Trimester of diagnosis                             |                                        |                                     | <.001 §   |
| <14 weeks                                          | 13 (7)                                 | 2 (4.3)                             |           |
| 14–27 weeks                                        | 22 (11.8)                              | 20 (42.6)                           |           |
| 28–40 weeks                                        | 151 (81.2)                             | 25 (53.2)                           |           |
| Current or former smoker                           | 10 (5.4)                               | 9 (19.6)                            | .004 §    |
| Chronic hypertension                               | 4 (2.2)                                | 4 (8.5)                             | .06 §     |
| Cardiac disease                                    | 3 (1.6)                                | 3 (6.4)                             | .1 §      |
| Asthma or other respiratory condition              | 13 (7)                                 | 10 (21.3)                           | .01 §     |
| Thrombophilia                                      | 3 (1.6)                                | 1 (2.1)                             | 1.0 §     |
| Rheumatologic disorder                             | 4 (2.2)                                | 1 (2.1)                             | 1.0 §     |
| Anemia                                             | 39 (21)                                | 12 (25.5)                           | .50 §     |
| Multiple gestation                                 | 2 (1.1)                                | 0 (0)                               | 1.0 §     |
| Prepregestational diabetes                         | 6 (3.2)                                | 2 (4.3)                             | .66 §     |
| GDMA (1 or 2)                                      | 8 (4.3)                                | 5 (10.6)                            | .15 §     |
| Preeclampsia                                       | 15 (8.1)                               | 6 (12.8)                            | .32 §     |
| Blood type                                         | (N=182)                                | (N=45)                              | .76 §     |
| A                                                   | 58 (31.9)                              | 12 (26.7)                           |           |
| B                                                   | 29 (15.9)                              | 9 (20)                              |           |
| AB                                                  | 8 (4.4)                                | 1 (2.2)                             |           |
| O                                                   | 87 (47.8)                              | 23 (51.1)                           |           |
| Home medications used                              |                                        |                                     |           |
| Plaquenil                                          | 3 (1.6)                                | 1 (2.1)                             | 1.0 §     |
| Steroids                                           | 4 (2.2)                                | 2 (4.3)                             | .35 §     |
| Antihypertensive                                   | 3 (1.6)                                | 2 (4.3)                             | .27 §     |
| Aspirin                                             | 27 (14.5)                              | 11 (23.4)                           | .14 §     |

All data presented as n (%) unless otherwise stated.

*Data presented as median (IQR).

†Mann–Whitney test used.

§ Fisher’s exact test used.

||Chi-square test used.
pregnancy and used manual chart review rather than ICD10 codes to obtain reliable and detailed information about patient clinical characteristics. Data were collected from three centers with a diverse patient population and payer mix, making our findings generalizable. We are limited by the relatively small cohort size, which may lead to an inability to detect some risk factors that could have contributed to severe/critical illness.

This study also had several limitations. Universal testing for SARS-CoV-2 was not available in the first weeks of data collection, and therefore only symptomatic women were tested initially. This may have increased the proportion of women with severe/critical illness in our cohort. The increased severity of disease in women diagnosed in the second trimester may have been due to selection bias, as universal screening likely led to an overrepresentation of asymptomatic women in the third trimester. Asymptomatic women or those with mild symptoms were likely not well-represented in our cohort since they were not screened in the first few weeks of the pandemic or were encouraged to remain at home. However, women who developed severe/critical COVID-19 disease in any trimester were included and therefore our evaluation of prediction of this level of disease should be robust.

Additionally, this study was performed based on patient data from early in the pandemic, when fewer treatments for severe and critical COVID-19 disease, such as remdesivir and dexamethasone were recommended. This may have contributed to the high rate of severe/critical disease (20.2%) seen in this cohort. Due to the testing strategy that was utilized, this rate should not be interpreted as the overall risk of developing severe/critical disease in pregnancy. However, the risk factors for the development of severe and critical diseases described here remain applicable.

Conclusions

In conclusion, we found that women infected with SARS-CoV-2 in pregnancy were more likely to develop severe or critical disease if they were diagnosed in the second trimester or had a history of smoking or respiratory disease. In our cohort, severity of disease was not impacted by obesity and age. Despite the rollout of multiple effective vaccines, pregnant women are less likely to be vaccinated and remain at risk for contracting COVID-19. The risk factors described here may be useful in counseling pregnant women on their individual risk of developing the severe or critical disease, and may help providers counsel women for vaccination during pregnancy.

Disclosure statement

The authors report no conflict of interest.

Author contributions

All authors contributed to the study conception and design. Data collection and analysis were performed by Megan E. Trostle, Meghana Limaye, Pooja Venkatesh, Meralis Lantigua Martinez, Lili Wei, Parita Sahani, Tracy B. Grossman, and Jessica A. Meyer. The first draft of the manuscript was written by Meghana Limaye and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by funds from New York University Grossman School of Medicine.

References

[1] COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Johns Hopkins University; 2000 [updated 2021 Feb 1]. Available from: https://coronavirus.jhu.edu/map.html (accessed 1 February 2021).

[2] Evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19. CDC [updated 2020 Nov 2]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/evidence-table.html (accessed 16 December 2020).

[3] Metz TD, Clifton RG, Hughes BL, et al. Disease severity and perinatal outcomes of pregnant patients with coronavirus disease 2019 (COVID-19). Obstet Gynecol. 2021;137(4):571–580.

[4] DeBolt CA, Bianco A, Limaye MA, et al. Pregnant women with severe or critical coronavirus disease 2019 have increased composite morbidity compared with nonpregnant matched controls. Am J Obstet Gynecol. 2021;224(5):510.e1–510.e12.

[5] Ellington S, Strid P, Tong V, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status — United States, January 22–June 7, 2020. Morbidity and Mortality Weekly Report. 2020;69:769–775.

[6] Badr DA, Mattern J, Carlin A, et al. Are clinical outcomes worse for pregnant women at >20 weeks’ gestation infected with coronavirus disease 2019? A multicenter case-control study with propensity score matching. Am J Obstet Gynecol. 2020;223(5):764–768.

[7] Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). WHO-China Joint Mission on Coronavirus Disease 2019/2020.
Available from: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf (accessed 26 March 2020).

[8] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242.

[9] Bhargava A, Fukushima EA, Levine M, et al. Predictors for Severe COVID-19 Infection. Clin Infect Dis. 2020;71(8):1962–1968.

[10] Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320.

[11] Galang RR, Newton SM, Woodworth KR, et al. Risk factors for illness severity among pregnant women with confirmed SARS-CoV-2 infection—surveillance for emerging threats to mothers and babies network, 22 state, local, and territorial health departments, March 29, 2020–March 5, 2021. Clin Infect Dis. 2021.

[12] Vousden N, Bunch K, Morris E, et al. The incidence, characteristics and outcomes of pregnant women hospitalized with symptomatic and asymptomatic SARS-CoV-2 infection in the UK from March to September 2020: a national cohort study using the UK Obstetric Surveillance System (UKOSS). PLOS One. 2021;16(5):e0251123.